MedPath

ARTERIOCYTE, INC.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:4
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (80.0%)
Not Applicable
1 (20.0%)

Applying Platelet Rich Plasma (PRP) Gel to Acute Deep Partial Thickness Thermal Injuries

Phase 1
Conditions
Acute Deep Partial Thickness Thermal Burns
First Posted Date
2014-06-23
Last Posted Date
2017-04-13
Lead Sponsor
Arteriocyte, Inc.
Target Recruit Count
36
Registration Number
NCT02169362
Locations
🇺🇸

Arizona Burn Center, Phoenix, Arizona, United States

🇺🇸

University of California, Davis Medica Center, Sacramento, California, United States

🇺🇸

MedStar Health Research Institute, Washington, District of Columbia, United States

and more 5 locations

Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds

Not Applicable
Terminated
Conditions
Diabetic Foot Ulcers
Pressure Ulcers
Venous Ulcers
First Posted Date
2014-02-26
Last Posted Date
2018-01-16
Lead Sponsor
Arteriocyte, Inc.
Target Recruit Count
1500
Registration Number
NCT02071979
Locations
🇺🇸

Good Samaritan Wound Care Center, Bakersfield, California, United States

🇺🇸

Sunnyside Foot and Ankle, Idaho Falls, Idaho, United States

🇺🇸

Wound Care Center, Englewood Hospital and Medical Center, Englewood, New Jersey, United States

and more 3 locations

Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns

Phase 1
Conditions
Acute Burns
First Posted Date
2013-05-01
Last Posted Date
2018-01-09
Lead Sponsor
Arteriocyte, Inc.
Target Recruit Count
42
Registration Number
NCT01843686
Locations
🇺🇸

University of California, Davis, Division of Burn Surgery, Sacramento, California, United States

🇺🇸

Medstar Health Research Institute, Washington, District of Columbia, United States

🇺🇸

University of Utah Hospital, Salt Lake City, Utah, United States

Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma

Phase 1
Completed
Conditions
Compartment Syndrome
First Posted Date
2013-04-23
Last Posted Date
2017-04-13
Lead Sponsor
Arteriocyte, Inc.
Target Recruit Count
5
Registration Number
NCT01837264
Locations
🇺🇸

Advocate Christ Medical Center, Oak Lawn, Illinois, United States

Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)

Phase 1
Completed
Conditions
Critical Limb Ischemia (CLI)
Peripheral Vascular Disease (PVD)
First Posted Date
2011-07-01
Last Posted Date
2017-01-24
Lead Sponsor
Arteriocyte, Inc.
Target Recruit Count
18
Registration Number
NCT01386216
Locations
🇺🇸

The Ohio State University Medical Center, Columbus, Ohio, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.